Search

Your search keyword '"Triggiani, Massimo"' showing total 767 results

Search Constraints

Start Over You searched for: Author "Triggiani, Massimo" Remove constraint Author: "Triggiani, Massimo"
767 results on '"Triggiani, Massimo"'

Search Results

2. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

3. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

5. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

7. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

8. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

9. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

11. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

12. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

13. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

14. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group

15. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

16. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

17. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice

18. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

19. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

20. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

21. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis

22. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study

23. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study

24. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

25. Severe asthma: One disease and multiple definitions

26. Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission

27. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis

29. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

30. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin

31. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

32. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

33. International Consensus on the Use of Genetics in the Management of Hereditary Angioedema

34. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

36. COVID 19: a clue from innate immunity

37. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

38. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome

40. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

41. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

42. Real-world effectiveness and characteristics of Super-Responders to Mepolizumab and Benralizumab in severe eosinophilic asthma and EGPA

43. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps

44. Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis

45. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial

46. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial

47. P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL

48. Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice

49. In memoriam: Lawrence M. Lichtenstein (1934-2022)

50. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Catalog

Books, media, physical & digital resources